[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652396":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":52,"collaborators":24,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":82,"whyStopped":24,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Vietnam Military Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"FSH 225 IU","EXPERIMENTAL","Participants assigned to this arm will receive a starting dose of 225 IU follicle-stimulating hormone (FSH) during progestin-primed ovarian stimulation (PPOS) for in vitro fertilization (IVF).",[13],"Drug: Follitropin Alfa (Follitrope)",{"label":15,"type":10,"description":16,"interventionNames":17},"FSH 300 IU","Participants assigned to this arm will receive a starting dose of 300 IU follicle-stimulating hormone (FSH) during progestin-primed ovarian stimulation (PPOS) for in vitro fertilization (IVF).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Follitropin Alfa (Follitrope)","Follicle-stimulating hormone (FSH) is administered by subcutaneous injection as the gonadotropin for ovarian stimulation in a progestin-primed ovarian stimulation (PPOS) protocol. Participants are randomized to receive either 225 IU or 300 IU of FSH daily according to their assigned study arm, and the assigned dose is maintained unchanged throughout the ovarian stimulation period.",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Truc Nhu Thanh Vo, PhD Student","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},"CONTACT","+84 0764681310","vonhuthanhtruc.art@gmail.com",[35],{"facility":36,"status":24,"city":37,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"An Sinh Hospital","Ho Chi Minh City","722210","Vietnam","VN",{"type":42,"coordinates":43},"Point",[44,45],106.62965,10.82302,{"lat":45,"lon":44},[48,49,51],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},{"name":24,"role":31,"phone":24,"phoneExt":24,"email":50},"trucvnt@ansinh.com.vn",{"name":27,"role":28,"phone":24,"phoneExt":24,"email":24},{"type":28,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Vo Nhu Thanh Truc","Head of IVF laboratory","100652396","225-iu-versus-300-iu-starting-fsh-dose-in-ppos-for-good-prognosis-women-100652396",false,"NCT07772375","225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women","A Randomized Controlled Trial Comparing 225 IU Versus 300 IU Starting Doses of Follicle-Stimulating Hormone in Progestin-Primed Ovarian Stimulation for Women With Good Prognosis","FSH-PPOS","Inclusion Criteria:\n\n* Female patient or oocyte donor aged \\\u003C35 years.\n* Body mass index (BMI) between 18 and 25 kg\u002Fm².\n* Normal ovarian reserve, defined by:\n\n  * Antral follicle count (AFC) ≥8 on ultrasound; and\n  * AMH level between 1.5 and 4.5 ng\u002FmL.\n* First IVF treatment cycle.\n* Controlled ovarian stimulation using a progestin-primed ovarian stimulation (PPOS) protocol with recombinant FSH and dydrogesterone.\n* Indication for in vitro fertilization using intracytoplasmic sperm injection (ICSI).\n* Indication for extended embryo culture to the blastocyst stage.\n* Willingness to participate in the study and provision of written informed consent.\n\nExclusion Criteria:\n\n* Polycystic ovary syndrome (PCOS) diagnosed according to the Rotterdam criteria, currently referred to as polyendocrine metabolic ovarian syndrome (PMOS).\n* Structural abnormalities of the ovaries.\n* Ovarian endometriosis.\n* Medical or gynecological conditions that may affect ovarian response to controlled ovarian stimulation.\n* Indication for luteinizing hormone (LH) supplementation during controlled ovarian stimulation.\n* Poor sperm quality, cryptozoospermia, surgically retrieved sperm (PESA, TESE, or microTESE), cryopreserved sperm, or donor sperm.\n* Indication for artificial oocyte activation (AOA) or rescue ICSI (R-ICSI).","FEMALE","18 Years","34 Years",{"count":67,"type":68},380,"ESTIMATED","INTERVENTIONAL",[71],"NA","This randomized controlled trial will compare two starting doses of follicle-stimulating hormone (FSH), 225 IU and 300 IU, during progestin-primed ovarian stimulation (PPOS) in women undergoing in vitro fertilization (IVF) who have a good reproductive prognosis. Participants will be randomly assigned to receive either 225 IU or 300 IU of FSH at the start of ovarian stimulation. The study will evaluate whether the starting FSH dose affects oocyte and embryo outcomes, with blastocyst formation as the primary outcome. Other outcomes will include oocyte morphology, fertilization, embryo development, and embryo quality. The findings may help determine an appropriate starting FSH dose for women with a good prognosis undergoing IVF using the PPOS protocol.",[74,75],"Infertility (IVF Patients)","Infertility Assisted Reproductive Technology",[77,78,79,80,81],"Progestin-primed ovarian stimulation","PPOS","FSH dose","Embryo quality","blastulation","NOT_YET_RECRUITING","2026-08-17",{"date":85,"type":86},"2026-08-19","ACTUAL",{"date":88,"type":68},"2026-08-15",{"date":90,"type":68},"2029-08-31",{"name":5,"class":6},1]